RxDoctor Payments Data

Pedro Santiago, MD

Internal Medicine · Humacao, PRNPI 1780965467

Payments from drug & device makers

$2,079in general payments, 2019–2025

Across 98 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$796
  • Sanofi$221
  • Boston Scientific$184
  • Boehringer Ingelheim$161
  • E.r. Squibb & Sons, L.L.C.$156
  • PBG Puerto Rico LLC$125
  • plus $436 from 8 others

What the payments were for

  • Food & beverage$2,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,079 in reported general payments places this provider in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,416
Medicare patients
32
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide225$223,070
EliquisApixaban261$176,011
Xigduo XrDapaglifloz Propaned/Metformin266$169,783
Trijardy XrEmpaglifloz/Linaglip/Metformin180$121,737
FarxigaDapagliflozin Propanediol192$120,941
TrulicityDulaglutide113$111,615
Synjardy XrEmpagliflozin/Metformin Hcl157$106,194
JardianceEmpagliflozin148$105,000
XareltoRivaroxaban144$95,897
SynthroidLevothyroxine Sodium859$75,056
SynjardyEmpagliflozin/Metformin Hcl70$36,146
JanumetSitagliptin Phos/Metformin Hcl32$30,378
LantusInsulin Glargine,hum.Rec.Anlog346$30,197
GlyxambiEmpagliflozin/Linagliptin47$28,370
Breo ElliptaFluticasone/Vilanterol62$27,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTrijardy Xr, Synjardy Xr, Jardiance, Synjardy, Glyxambi$161$416,260630 claims
Novo NordiskOzempic$33$223,070225 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$16$139,871230 claims
Lilly USA, LLCTrulicity, Humalog$57$124,123196 claims
Johnson & JohnsonXarelto$94$95,897144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →